Circulating tumour DNA (ctDNA) is a potential biomarker that could contribute to more
judicious patient selection for personalised treatment. This review and meta-analysis gives …

Background Recurrence rates after resection of colorectal cancer liver metastases (CRLM)
are high and correlate with worse survival. Postoperative circulating tumour DNA (ctDNA) is …

Background In patients with resectable colorectal liver metastases (CRLM), the role of pre-
and postoperative systemic therapy continues to be debated. Previous studies have shown …

Background We investigate the current knowledge on circulating tumour DNA (ctDNA) and
its clinical utility in predicting outcomes in patients with metastatic colorectal cancer (mCRC) …

The recurrence rate of colorectal liver metastases (CRLM) patients treated with curative
intent is above 50%. Standard of care surveillance includes intensive computed …

e15131 Background: In pts with metastatic colorectal cancer (mCRC), the resection of
isolated CLM is potentially curative. Previous studies have shown that ctDNA can be …

PURPOSE Prognostic tools to estimate the risk of relapse for patients with liver-limited
metastatic colorectal cancer (LL-mCRC) undergoing resection with curative intent are …

Background The recurrence rate after hepatic resection of colorectal liver metastases
(CRLM) remains high. This study aimed to investigate postoperative circulating tumor DNA …

Background The surgical resection of colorectal cancer with liver metastases (CLM) has
proven to be the most important modality for long-term survival, while effective biomarkers …

Background For patients with metastatic colorectal cancer, stratification for treatment
(surgery or chemotherapy) is often based on crude clinicopathological characteristics like …